From investors to startups to the world’s largest healthcare companies, clients turn to us on a full range of transactions and other legal matters.
Companies appreciate our depth of experience in areas including pharmaceuticals, biotechnology, and diagnostic and medical devices. Since 2010, we have completed more than 850 capital markets transactions in healthcare, totaling over $2 trillion. Over the same peroid, we have advised on approximately 300 M&A transactions, with a cumulative deal value of approximately $1.4 trillion and a market share of more than 20%, according to data from LSEG Data & Analytics.
Healthcare and life sciences clients trust in our understanding of the complex issues they face in acquisitions, divestitures, joint ventures, partnerships, strategic alliances, licensing arrangements, collaborations, distribution agreements, internal investigations and litigation.
Many transactions and other matters have an intellectual property component. Clients appreciate that our team includes lawyers with strong biomedical backgrounds such as Ph.D.s and biomedical engineering degrees.
Aggregate value of more than 850 capital markets transactions since 2010
Source: LSEG Data & Analytics
We work with top multinationals and are a firm of choice for companies going public. IPOs include ACELYRIN, American Well, Bausch + Lomb, BioNTech, CureVac, GoodRx, Signify Health, Royalty Pharma and Vaccitech.
Our M&A clients include leading developers of therapies, treatments and devices, including AstraZeneca, Bausch Health, Bristol Myers Squibb, Charles River, Gilead, Novo Nordisk, Pfizer, Roche and Smith+Nephew.
Numerous healthcare companies and credit arrangers have turned to us for advice on revolving and term loan facilities and on bridge loans facilities entered into in conjunction with business combinations.
We advise clients globally on a range of transactions, including complex licensing and collaboration arrangements, the disposal of research and development programs, and the acquisition of product rights.
We advise clients on litigation and enforcement involving alleged bribery, false advertising and fraud, product safety violations, off-label promotion and patent misuse, as well as securities litigation.